Dr. Reddy’s Laboratories (RDY) to Release Quarterly Earnings on Tuesday

Dr. Reddy’s Laboratories (NYSE:RDY) is anticipated to announce its Q4 24/25 earnings results before the market opens on Tuesday, May 6th. Analysts expect Dr. Reddy’s Laboratories to post earnings of $0.20 per share and revenue of $83.70 billion for the quarter.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, analysts expect Dr. Reddy’s Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Dr. Reddy’s Laboratories Price Performance

Shares of NYSE:RDY opened at $13.95 on Tuesday. The stock has a fifty day moving average of $13.18 and a 200-day moving average of $14.19. The company has a market capitalization of $11.65 billion, a PE ratio of 22.21 and a beta of 0.51. Dr. Reddy’s Laboratories has a one year low of $12.26 and a one year high of $16.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.